RU97112616A - MEDICINAL PRODUCT FOR TREATMENT OF PROCTOLOGICAL DISEASES - Google Patents
MEDICINAL PRODUCT FOR TREATMENT OF PROCTOLOGICAL DISEASESInfo
- Publication number
- RU97112616A RU97112616A RU97112616/14A RU97112616A RU97112616A RU 97112616 A RU97112616 A RU 97112616A RU 97112616/14 A RU97112616/14 A RU 97112616/14A RU 97112616 A RU97112616 A RU 97112616A RU 97112616 A RU97112616 A RU 97112616A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- medicinal product
- agent
- following ratio
- active principle
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 2
- 241000379194 Abies sibirica Species 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
Claims (1)
Действующее начало - 5,54-15,02
Основа - 84,98-94,46,
при этом действующее начало содержит компоненты в следующем соотношении, мас.%:
Экстракт пихты сибирской - 13,32-45,13
Местноанестезирующий агент - 7,12-36,10
Антисептический агент - 0,13-0,72
Смягчающий агент - 18,05-71,17,
а основа содержит компоненты в следующем соотношении, мас.%:
Гелеобразующий агент - 1,41-2,33
Дистиллированная вода - 97,67-98,59A drug for the treatment of proctologic diseases, including the active principle and the basis, characterized in that as the main component of the active principle, it contains an extract of Siberian fir in the following ratio, wt.%:
The current beginning - 5.54-15.02
Basis - 84.98-94.46,
while the active principle contains components in the following ratio, wt.%:
Siberian fir extract - 13.32-45.13
Local anesthetic agent - 7.12-36.10
Antiseptic agent - 0.13-0.72
Emollient agent - 18.05-71.17,
and the base contains components in the following ratio, wt.%:
Gelling agent - 1.41-2.33
Distilled water - 97.67-98.59
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU97112616A RU2152205C1 (en) | 1997-07-23 | 1997-07-23 | Drug for treatment of patients with proctological diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU97112616A RU2152205C1 (en) | 1997-07-23 | 1997-07-23 | Drug for treatment of patients with proctological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU97112616A true RU97112616A (en) | 1999-06-10 |
| RU2152205C1 RU2152205C1 (en) | 2000-07-10 |
Family
ID=20195603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU97112616A RU2152205C1 (en) | 1997-07-23 | 1997-07-23 | Drug for treatment of patients with proctological diseases |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2152205C1 (en) |
-
1997
- 1997-07-23 RU RU97112616A patent/RU2152205C1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE200733T1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING FLUOXETINE | |
| ATE211907T1 (en) | OSMOTIC DRUG RELEASE SYSTEM | |
| KR960700742A (en) | ATOPIC DISEASE REMEDY | |
| FI956014A0 (en) | Use of non- and decapeptides in the manufacture of a medicament for the treatment of AIDS | |
| ES2176322T3 (en) | NEW OPIOID PEPTIDES FOR THE TREATMENT OF PAIN AND ITS USE. | |
| UY26372A1 (en) | "IMIDAZO-3-IL-AMINAS BICÍCLICAS PROCEDURE FOR ITS PREPARATION AND DRUGS THAT CONTAIN THEM" | |
| PT998287E (en) | USES OF LEVOBUPIVACAINE | |
| ES2153906T3 (en) | USE OF INCENSE FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| HUP0100024A3 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
| ATE262893T1 (en) | DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES | |
| DE69500673D1 (en) | Medicines for the therapeutic and prophylactic treatment of diseases caused by hyperplasia of the smooth muscle cells | |
| CA2340734A1 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| MX9707642A (en) | Pharmaceutical agents for the treatment of alzheimer's disease. | |
| DK1027325T3 (en) | Lipophilic diesters of chelating agents | |
| CA2091134A1 (en) | Therapeutic agent for threatened abortion | |
| MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
| RU97112616A (en) | MEDICINAL PRODUCT FOR TREATMENT OF PROCTOLOGICAL DISEASES | |
| KR970061248A (en) | 1, 1, 2-triphenylbut-1-ene derivative for the treatment of Alzheimer's disease | |
| EA200401295A1 (en) | STATIN THERAPY TO ENHANCE SUPPORT OF COGNITIVE FUNCTION | |
| DE69729201D1 (en) | SULPHONE FLUORIDE FOR TREATING ALZHEIMERISCHEN DISEASE | |
| DE50202865D1 (en) | PREPARATION OF PURE STEREOISOMERS OF TRICYCLO [5.2.1.0 (2.6)] -DEC-9-YL-XANTHOGENATE AND THEIR USE AS DRUGS | |
| CA2423288A1 (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
| RU97104062A (en) | APPLICATION OF SELEGYLIN FOR TREATMENT OF EPILEPTIC DISEASES | |
| Nicholson | Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention" high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended? | |
| RU99107243A (en) | MEDICAL AND PREVENTIVE MEANS OF A WIDE SPECTRUM OF ACTION |